408 related articles for article (PubMed ID: 21651967)
1. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
2. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
3. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations.
Hu K; Li J; Shen Y; Lu W; Gao X; Zhang Q; Jiang X
J Control Release; 2009 Feb; 134(1):55-61. PubMed ID: 19038299
[TBL] [Abstract][Full Text] [Related]
4. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
[TBL] [Abstract][Full Text] [Related]
5. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
6. Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations.
Chen J; Zhang C; Liu Q; Shao X; Feng C; Shen Y; Zhang Q; Jiang X
J Drug Target; 2012 Feb; 20(2):174-84. PubMed ID: 21992548
[TBL] [Abstract][Full Text] [Related]
7. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.
Lu W; Wan J; She Z; Jiang X
J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471
[TBL] [Abstract][Full Text] [Related]
8. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain.
Parikh T; Bommana MM; Squillante E
Eur J Pharm Biopharm; 2010 Mar; 74(3):442-50. PubMed ID: 19941957
[TBL] [Abstract][Full Text] [Related]
10. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes.
Pang Z; Gao H; Yu Y; Chen J; Guo L; Ren J; Wen Z; Su J; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):284-92. PubMed ID: 21651966
[TBL] [Abstract][Full Text] [Related]
11. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery.
Lu W; Zhang Y; Tan YZ; Hu KL; Jiang XG; Fu SK
J Control Release; 2005 Oct; 107(3):428-48. PubMed ID: 16176844
[TBL] [Abstract][Full Text] [Related]
12. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
13. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
Wen Z; Yan Z; He R; Pang Z; Guo L; Qian Y; Jiang X; Fang L
Drug Deliv; 2011 Nov; 18(8):555-61. PubMed ID: 21812752
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
15. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.
Huang R; Han L; Li J; Ren F; Ke W; Jiang C; Pei Y
J Gene Med; 2009 Sep; 11(9):754-63. PubMed ID: 19554623
[TBL] [Abstract][Full Text] [Related]
17. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.
Wen Z; Yan Z; Hu K; Pang Z; Cheng X; Guo L; Zhang Q; Jiang X; Fang L; Lai R
J Control Release; 2011 Apr; 151(2):131-8. PubMed ID: 21362449
[TBL] [Abstract][Full Text] [Related]
18. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery.
Mei H; Shi W; Pang Z; Wang H; Lu W; Jiang X; Deng J; Guo T; Hu Y
Biomaterials; 2010 Jul; 31(21):5619-26. PubMed ID: 20413154
[TBL] [Abstract][Full Text] [Related]
19. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery.
Yu Y; Pang Z; Lu W; Yin Q; Gao H; Jiang X
Pharm Res; 2012 Jan; 29(1):83-96. PubMed ID: 21979908
[TBL] [Abstract][Full Text] [Related]
20. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats.
Pang Z; Feng L; Hua R; Chen J; Gao H; Pan S; Jiang X; Zhang P
Mol Pharm; 2010 Dec; 7(6):1995-2005. PubMed ID: 20957995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
